1000 members: a milestone of Chinese Antibody Society


“Jingle bells, jingle bells, jingle all the way!” As Christmas approaches, we are ready to embrace the coming year of 2018. At this festive season, CAS sees its 1000th registered member on Dec 10th 2017.

The president of CAS, Dr. Shouye Wang, highlights this historic moment: “On behalf of CAS, I thank the trust of all members to our society. We will continue to make CAS a top platform for the interaction and communication for all members across the globe. CAS also expects to bring together the strength and wisdom of its members to pave the way for Chinese antibody therapeutics to the world. At this moment, I would like to wish a Merry Christmas and Happy New Year to you all.”

Since the initiation of CAS member registration on Jan 23th 2017, we see the 1000th registered member a significant breakthrough not only for CAS, but for the entire Chinese antibody community as well. As the director of board, Dr. Dechao Yu, puts it, “no one in drug industry today can overlook antibody.” CAS as a community of antibody drug R&D specialists, it will keep acting as a bridge between markets in China and in the US and even in the rest of the world. The massive growth of our community has made our influence greater than ever.

There is still a long way ahead of us. We now make a conclusion to the current registration status of the society to make better service to our community in the coming year.

A review of our 1000 members registration

Let us first congratulate our 1000th registered member: Jianming Jimmy Hao. Jianming Jimmy Hao is a partner at Fox Rothschild LLP. He focuses on patent preparation/prosecution and counsels on issues including antibodies, biologics, biosimilars, trademark, licensing, FTO, opinions, IP litigations, corporate, VC and non-profit. He provided representation to notable transactions, including Alexion’s acquisition of Synageva ($8.4 billion), Humanwell’s acquisition of Epic ($550 million), BMS’s acquisition of Amira ($475 million), licensing and collaboration deals involving universities. Jimmy received a PhD from Columbia University, postdoc trainings at Harvard, a JD from Boston College, an MBA from Cornell University and a BS from Nankai University. He is a co-founder and board member of BioKatalyst.

The geographical analysis of all registered members shows a global distribution where 50% are based in the US and 45% are based in China. In the US, 45% of members are based in Massachusetts followed by California, New Jersey, Pennsylvania and New York State. The total number of members in these states counts for 80% of the entire US members, which is consistent with the popularity of antibody drugs in the US. In China, 38% of the members are located in Shanghai followed by Jiangsu, Beijing, Guangdong and Zhejiang, which in total counts for 85% of the entire community in China and is consistent with those areas being the major developmental centers of antibody drugs in China. Judging by the career, 89% of our members are working in drug industry, 10% are from academia, and the rest are from healthcare, law and investment. This shows a vast diversity of our community.

Other than our 1,000 registered members, there are more than 9,000 users from different background subscribed to our WeChat account that brings different perspectives to the society. Such a significant number of users also act as a major drive for CAS to provide the best service. We expect more friends to join us. In the New Year, we will strive to offer supreme services to our community:

  1. Free access to the webinar which is open only to the members of the society

This series of webinars covers all major topics for the R&D of antibody therapeutics, including discovery, CMC, regulation, clinical trial, IP and investment. The webinars are presented by senior specialists in corresponding fields and are interactive to all attendees. We have held seven of this webinar series and will continue to organize one for every month. Please visit (http://chineseantibody.org/webinar/) for more details.

2. Member-only WeChat group

This group provides a specialized platform for CAS members to discuss R&D, technology transfer, employment and entrepreneurship. Meanwhile, members are allowed to post advertising and employment information for their company.

3. Annual meeting to the members

The second annual meeting of CAS will be held in Cambridge, MA, US on April 29th 2018. Please see http://chineseantibody.org/2nd-annual-conference/ for more details. Specialists in antibody therapeutics will liaise with the fellow experts across the globe to discuss the latest development in the field.

4. Free access to activities regularly held by the society

We recently brought forward a delegation trip to top companies in biopharmaceuticals, which is hosted by 3Sbio. Inc (please see http://chineseantibody.org/membersday/ for report). We will keep organizing similar networking activities like this in the coming year.

5. Discounts to major conferences in antibody therapeutics field (PEGS, AET and Peptalk etc.)

CAS has reached agreement with CHI (Cambridge Health Institute), the host of PEGS and Peptalk, to allow members of CAS to enjoy a 20% discount on the registration fee. Moreover, CAS has negotiated a 10% discount from Knect365 which is the host of AET. CAS will also host some member-only activities during the conference, such as industry-sponsored networking or academic events.

6. More to be expected…

We strive to provide more networking events to top experts in the field and other welfares to our members. Please keep in touch in the year 2018.